Informações:
Falhas:
ID
15114
Descrição
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet; ODM derived from: https://clinicaltrials.gov/show/NCT00118950
Link
https://clinicaltrials.gov/show/NCT00118950
Palavras-chave
Versões (1)
- 16/05/2016 16/05/2016 -
Transferido a
16 de maio de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Diabetes Mellitus, Type 2 NCT00118950
Eligibility Diabetes Mellitus, Type 2 NCT00118950
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT00118950
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
diabetes type 2
Item
type-2 diabetes, defined as:
boolean
C0011849 (UMLS CUI [1,1])
C0441730 (UMLS CUI [1,2])
C0441730 (UMLS CUI [1,2])
age at onset
Item
age at onset of diabetes ≥ 40 years
boolean
C0001779 (UMLS CUI [1,1])
C0332162 (UMLS CUI [1,2])
C0332162 (UMLS CUI [1,2])
serum c-peptide
Item
fasting serum c-peptide ≥ 300 pmol/l or a non-fasting or glucagon-stimulated serum c-peptide ≥ 600 pmol/l
boolean
C0006558 (UMLS CUI [1])
ketonuria or ketoacidosis
Item
no history of ketonuria or ketoacidosis .
boolean
C0162275 (UMLS CUI [1,1])
C0011880 (UMLS CUI [1,2])
C0011880 (UMLS CUI [1,2])
bmi
Item
bmi ≤ 27 kg/m2.
boolean
C1305855 (UMLS CUI [1])
plasma-glucose
Item
fasting plasma-glucose ≥ 6.5 mmol/l after at least one month of diet-only treatment.
boolean
C0202042 (UMLS CUI [1])
hba1c
Item
hba1c ≤ 9.5% at ongoing oral anti-hyperglycaemic agents. hba1c ≥ 6.5% after minimum one month of diet-only treatment.
boolean
C0019018 (UMLS CUI [1])
weight-loss
Item
weight-loss of no more than 5.0 kg during the last 6 months prior to enrolment.
boolean
C1262477 (UMLS CUI [1,1])
C0439792 (UMLS CUI [1,2])
C0439792 (UMLS CUI [1,2])
diabetes type 1
Item
type-1 diabetes
boolean
C0011849 (UMLS CUI [1,1])
C0441729 (UMLS CUI [1,2])
C0441729 (UMLS CUI [1,2])
diabetes type
Item
insulin-treated type-2 diabetes
boolean
C0011849 (UMLS CUI [1,1])
C0441730 (UMLS CUI [1,2])
C0745343 (UMLS CUI [1,3])
C0441730 (UMLS CUI [1,2])
C0745343 (UMLS CUI [1,3])
diabetes
Item
secondary diabetes, heart-failure
boolean
C0011849 (UMLS CUI [1,1])
C0277555 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
C0277555 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
creatinine
Item
serum-creatinine above the upper limit
boolean
C0201976 (UMLS CUI [1])
asat
Item
serum-asat elevated more than 3 fold above the upper limit
boolean
C0201899 (UMLS CUI [1])
blood coagulating factor
Item
factor ii-vii-x decreased below 0.7
boolean
C0005789 (UMLS CUI [1,1])
C0547047 (UMLS CUI [1,2])
C0547047 (UMLS CUI [1,2])
life shortening comorbidity
Item
ongoing coexisting illnesses with a life-shortening prognosis
boolean
C0009488 (UMLS CUI [1,1])
C0023671 (UMLS CUI [1,2])
C0023671 (UMLS CUI [1,2])
mental retardation
Item
mental retardation or reduced intellectual behaviour
boolean
C0025362 (UMLS CUI [1])
pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
drug-abuse
Item
history of drug-abuse or hba1c>10.5% at two separate visits with at least one month interval during treatment-periods.
boolean
C0013146 (UMLS CUI [1])
C0019018 (UMLS CUI [2])
C0019018 (UMLS CUI [2])